https://doi.org/10.4081/hmr.v2i7.414

Palonosetron, second generation 5-HT3 antagonist: a new perspective in CINV management

Vol. 2 No. 7: New Insights in Hematology, Venice (Italy), May 14-17, 2006
Published: June 8, 2009
Abstract Views: 184
PDF: 207
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Authors

PP Piccaluga
support@pagepress.org
It is well established that the majority of cancer patients who undergo moderately or highly emetogenic cytotoxic treatment without receiving prophylactic antiemetics will experience chemotherapy-induced nausea and vomiting (CINV). Although the exact mechanisms of CINV are not fully known, it is clear from preclinical experiments and more than 15 years of clinical investigations that serotonin plays a major role in initiating nausea and vomiting associated with emetogenic chemotherapy. Emetogenic chemotherapy damages the gastrointestinal mucosa, causing the release of serotonin (5-hydroxytryptamine [5-HT]) from enterochromaffin cells in the small intestine, which, in turn, activates 5-HT3 receptors located on vagal afferents.

Dimensions

Altmetric

PlumX Metrics

Downloads

Citations

Crossref
Scopus
Google Scholar
Europe PMC

Supporting Agencies

How to Cite

Piccaluga, P. (2009). Palonosetron, second generation 5-HT3 antagonist: a new perspective in CINV management. Hematology Meeting Reports (formerly Haematologica Reports), 2(7). https://doi.org/10.4081/hmr.v2i7.414
Authors who publish with this journal agree to the following terms: Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).